Product Information
QC IBUPROFEN 200 MG TABLET is a generic product labeled by Chain Drug Marketing Association, priced at $0.0331 per EA under NDC 83324005624. Its NADAC has been published 88 times since Jan 29, 2025.
FDA first approved this application on Mar 1, 1999.
Strength
200 mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
83324005624
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA075010FDA Approved
3/1/1999
On Market Since
8/13/2024
Pharmacological Classes
Price Statistics
The NADAC for QC IBUPROFEN 200 MG TABLET has been published 88 times since Jan 29, 2025, and over the history we have for it it has declined 3.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0331 per EA |
|---|---|
| All-time high | $0.0370 (Nov 12, 2025) |
| All-time low | $0.0313 (May 21, 2025) |
| 52-week high | $0.0370 |
| 52-week low | $0.0320 |
| Median price | $0.0329 |
| Average price | $0.0336 |
| Largest weekly change | -5.2% (Dec 17, 2025) |
| Weeks tracked | 88 |
| Tracking since | Jan 29, 2025 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC IBUPROFEN 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for QC IBUPROFEN 200 MG TABLET, manufactured by Chain Drug Marketing Association, is $0.0331 per EA (NDC 83324005624), effective Sep 30, 2026.
How has the price of QC IBUPROFEN 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for QC IBUPROFEN 200 MG TABLET has declined 3.4%. It has been tracked across 88 weekly CMS publications since Jan 29, 2025.
What are the highest and lowest recorded NADAC prices for QC IBUPROFEN 200 MG TABLET?
Since Jan 29, 2025, the NADAC for QC IBUPROFEN 200 MG TABLET has ranged from a low of $0.0313 (May 21, 2025) to a high of $0.0370 (Nov 12, 2025), with a median of $0.0329 per EA.
Are there cheaper alternatives to QC IBUPROFEN 200 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN 200 MG TABLET, is $0.0269 per EA — about 19% below QC IBUPROFEN 200 MG TABLET.
Who manufactures QC IBUPROFEN 200 MG TABLET?
QC IBUPROFEN 200 MG TABLET (NDC 83324005624) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.